Rezaeian Ahmad, Kargoshaei Amirabbas, Rastegar Zahra
Department of Otolaryngology, School of Medicine, Al-Zahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2021 Dec 25;10:51. doi: 10.4103/abr.abr_30_20. eCollection 2021.
Considering the effect of beclomethasone on allergic rhinitis or nasal polyps, it has been attempted to find the best method of using this drug to have the maximum effect and increase the patients' satisfaction. Therefore, the aim of this study was to compare the efficacy of beclomethasone aerosol and aqueous nasal sprays in the patients with nasal polyps.
This double-blind randomized clinical trial was conducted on 60 patients with nasal polyps. The patients were divided into two groups. The first group (beclomethasone dipropionate aqueous [BD-AQ] group) was treated with daily two puffs of beclomethasone aqueous nasal spray 50 μg in each nostril, and the second group (beclomethasone dipropionate aerosol [BD-A] group) was treated with two puffs of aerosol beclomethasone 50 μg in each nostril daily for 6 months. At the beginning of the study, the sino-nasal outcome test-22 (SNOT-22) and Lund-Mackay scores were recorded after the evaluation of disease status and the severity of symptoms.
The results of this study demonstrated that the mean changes in Lund-Mackay and SNOT-22 scores (83 ± 6.30 and 4.25 ± 31.60, respectively) in the BD-A group were significantly higher than the BD-AQ group (2.01 ± 3.87and 9.83 ± 24.13, respectively) ( < 0.05), but there was no significant difference in the patients' satisfaction between the two groups ( > 0.05).
According to the results of this study, patients with nasal polyps showed a significant improvement following both the interventions, but the disease severity in the BD-A group was significantly higher than the BD-AQ group based on the mean values of Lund-Mackay score.
考虑到倍氯米松对过敏性鼻炎或鼻息肉的疗效，人们一直在尝试寻找使用该药物的最佳方法，以达到最大效果并提高患者满意度。因此，本研究的目的是比较倍氯米松气雾剂和鼻用喷雾剂对鼻息肉患者的疗效。
本双盲随机临床试验对60例鼻息肉患者进行。患者分为两组。第一组（二丙酸倍氯米松水剂[BD-AQ]组）每天每侧鼻孔使用两喷50μg的倍氯米松鼻用喷雾剂，第二组（二丙酸倍氯米松气雾剂[BD-A]组）每天每侧鼻孔使用两喷50μg的倍氯米松气雾剂，持续6个月。在研究开始时，在评估疾病状态和症状严重程度后记录鼻窦结局测试-22（SNOT-22）和Lund-Mackay评分。
本研究结果表明，BD-A组Lund-Mackay和SNOT-22评分的平均变化（分别为83±6.30和4.25±31.60）显著高于BD-AQ组（分别为2.01±3.87和9.83±24.13）（<0.05），但两组患者的满意度无显著差异（>0.05）。
根据本研究结果，两种干预措施后鼻息肉患者均有显著改善，但基于Lund-Mackay评分的平均值，BD-A组的疾病严重程度显著高于BD-AQ组。
